GT199700074A - Derivados de 2-(2-oxo-etiliden)-imidazolidin-4-ona - Google Patents

Derivados de 2-(2-oxo-etiliden)-imidazolidin-4-ona

Info

Publication number
GT199700074A
GT199700074A GT199700074A GT199700074A GT199700074A GT 199700074 A GT199700074 A GT 199700074A GT 199700074 A GT199700074 A GT 199700074A GT 199700074 A GT199700074 A GT 199700074A GT 199700074 A GT199700074 A GT 199700074A
Authority
GT
Guatemala
Prior art keywords
derivatives
etiliden
imidazolidin
ona
oxo
Prior art date
Application number
GT199700074A
Other languages
English (en)
Inventor
Joseph Peter Lyssikatos
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT199700074A publication Critical patent/GT199700074A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

ESTA INVENCION SE REFIERE A UNA SERIE DE NUEVOS DERIVADOS DE: 2(2OXOETILIDEN)IMIDAZOLIDIN4ONA QUE PRESENTAN ACTIVIDAD COMO INHIBIDORES DE LA ENZIMA FARNESIL TRANSFERASA DE PROTEINA Y SE CREE QUE SON UTILES COMO AGENTES CONTRA EL CANCER Y ANTITUMORALES. ESTA INVENCION SE REFIERE ADEMAS A PROCEDIMIENTOS DE USO DE TALES COMPUESTOS EN EL TRATAMIENTO O PREVENCION DE CANCER EN UN MAMIFERO, EN PARTICULAR EN UN SER HUMANO, Y A COMPOSICIONES QUE CONTIENEN DICHOS COMPUESTOS.
GT199700074A 1996-06-27 1997-06-12 Derivados de 2-(2-oxo-etiliden)-imidazolidin-4-ona GT199700074A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2069696P 1996-06-27 1996-06-27

Publications (1)

Publication Number Publication Date
GT199700074A true GT199700074A (es) 1998-12-04

Family

ID=21800047

Family Applications (1)

Application Number Title Priority Date Filing Date
GT199700074A GT199700074A (es) 1996-06-27 1997-06-12 Derivados de 2-(2-oxo-etiliden)-imidazolidin-4-ona

Country Status (13)

Country Link
US (1) US6071935A (es)
EP (1) EP0907649A1 (es)
JP (1) JPH11512750A (es)
AP (1) AP9701039A0 (es)
AU (1) AU2710597A (es)
BR (1) BR9709974A (es)
CA (1) CA2259222A1 (es)
GT (1) GT199700074A (es)
ID (1) ID17053A (es)
MA (1) MA26432A1 (es)
TN (1) TNSN97110A1 (es)
WO (1) WO1997049700A1 (es)
ZA (1) ZA975675B (es)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0760239A3 (en) * 1995-09-01 1999-04-14 Pfizer Inc. Therapeutic agents for use in cancer therapy
US20030114503A1 (en) * 1997-06-16 2003-06-19 Pfizer Inc. Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the treatment of cancer
JPH11236333A (ja) * 1997-12-30 1999-08-31 Pfizer Prod Inc 抗ガン剤として有用なイミダゾリン−４−オン誘導体
EP1006113A1 (en) * 1998-12-02 2000-06-07 Pfizer Products Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use to inhibit abnormal cell growth
US6174903B1 (en) 1998-12-28 2001-01-16 Pfizer Inc. Imidazolidin-4-one derivatives useful as anticancer agents
JP2004516287A (ja) 2000-12-19 2004-06-03 ファイザー・プロダクツ・インク ６−［（４−クロロ−フェニル）−ヒドロキシ−（３−メチル−３ｈ−イミダゾール−４−イル）−メチル］−４−（３−エチニル−フェニル）−１−メチル−１ｈ−キノリン−２−オン，２，３−ジヒドロキシブタン二酸塩の結晶形および製造方法
WO2003000194A2 (en) 2001-06-21 2003-01-03 Pfizer Inc. Thienopyridine and thienopyrimidine anticancer agents
US6740757B2 (en) 2001-08-29 2004-05-25 Pfizer Inc Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer
AU2003206068A1 (en) * 2002-03-01 2003-09-16 Pfizer Inc. Indolyl-urea derivatives of thienopyridines useful as anti-angiogenic agents
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
UA77303C2 (en) * 2002-06-14 2006-11-15 Pfizer Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
CA2497628A1 (en) * 2002-09-05 2004-03-18 Medimmune, Inc. Methods of preventing or treating cell malignancies by administering cd2 antagonists
US8034831B2 (en) * 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
BR0317548A (pt) * 2002-12-19 2005-11-22 Pfizer Compostos de indazole e composições farmacêuticas para a inibição de proteìnas-cinases e métodos para o seu uso
KR101224235B1 (ko) 2003-04-11 2013-01-25 메디뮨 엘엘씨 재조합 ｉｌ­９ 항체 및 그의 용도
US20060228350A1 (en) * 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
EP2272566A3 (en) 2003-08-18 2013-01-02 MedImmune, LLC Humanisation of antibodies
DE602004017479D1 (de) * 2003-08-29 2008-12-11 Pfizer Als neue antiangiogene mittel geeignete thienopyridinphenylacetamide und derivate davon
MXPA06002256A (es) * 2003-08-29 2006-05-17 Pfizer Naftaleno carboxamidas y sus derivados utiles como agentes anti-angiogenicos.
UA82577C2 (en) * 2003-12-23 2008-04-25 Пфайзер Инк. Quinoline derivatives
BRPI0509580A (pt) * 2004-03-30 2007-11-27 Pfizer Prod Inc combinações de inibidores de transdução de sinal
JP4842929B2 (ja) 2004-05-27 2011-12-21 ファイザー・プロダクツ・インク 癌治療に有用なピロロピリミジン誘導体
AU2005276132B2 (en) * 2004-08-26 2011-09-29 Pfizer Inc. Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
MX2007001986A (es) * 2004-08-26 2007-05-10 Pfizer Compuestos de aminoheteroarilo como inhibidores de proteina quinasa.
RS51362B (en) 2004-08-26 2011-02-28 Pfizer Inc. ENANTIOMERALLY PURE AMINOHETEROARYL UNITS AS PROTEIN KINASE INHIBITORS
ES2334246T3 (es) * 2004-08-30 2010-03-08 Janssen Pharmaceutica Nv Derivados triciclos de adamantilamida como inhibidores de la 11-beta-hidroxiesteroide-deshidrogenasa.
AU2005299355A1 (en) 2004-10-27 2006-05-04 Medimmune, Llc Modulation of antibody specificity by tailoring the affinity to cognate antigens
US20060107555A1 (en) * 2004-11-09 2006-05-25 Curtis Marc D Universal snow plow adapter
WO2006102095A2 (en) 2005-03-18 2006-09-28 Medimmune, Inc. Framework-shuffling of antibodies
AU2006261920A1 (en) 2005-06-23 2007-01-04 Medimmune, Llc Antibody formulations having optimized aggregation and fragmentation profiles
ES2546069T3 (es) 2005-09-07 2015-09-18 Amgen Fremont Inc. Anticuerpos monoclonales humanos para quinasa-1 de tipo receptor de activina (ALK-1)
WO2007035744A1 (en) 2005-09-20 2007-03-29 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
EP2021338A1 (en) 2006-05-09 2009-02-11 Pfizer Products Inc. Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
DK2056874T3 (da) 2006-08-21 2012-10-15 Hoffmann La Roche Tumorterapi med et anti-vegf-antistof
PL2292663T3 (pl) 2006-08-28 2014-03-31 Kyowa Hakko Kirin Co Ltd Antagonistyczne ludzkie przeciwciała monoklonalne swoiste wobec ludzkiego LIGHT
EP2068923A4 (en) 2007-03-30 2010-11-24 Medimmune Llc ANTIBODIES HAVING REDUCED DEAMIDATION PROFILES
AU2008319298B2 (en) 2007-10-31 2014-07-31 Medimmune, Llc Protein scaffolds
US20120189641A1 (en) 2009-02-25 2012-07-26 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
EP2400990A2 (en) 2009-02-26 2012-01-04 OSI Pharmaceuticals, LLC In situ methods for monitoring the emt status of tumor cells in vivo
EP2401613A2 (en) 2009-02-27 2012-01-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
EP2401614A1 (en) 2009-02-27 2012-01-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2011109572A2 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
CA2783665A1 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2012103165A2 (en) 2011-01-26 2012-08-02 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
US20120214830A1 (en) 2011-02-22 2012-08-23 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
US9896730B2 (en) 2011-04-25 2018-02-20 OSI Pharmaceuticals, LLC Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
KR102268351B1 (ko) 2012-07-25 2021-06-22 셀덱스 쎄라퓨틱스, 인크. 항-kit 항체 및 그의 용도
AU2013329311A1 (en) 2012-10-09 2015-04-30 Igenica Biotherapeutics, Inc. Anti-C16orf54 antibodies and methods of use thereof
US9180185B2 (en) 2013-01-11 2015-11-10 Hoffman-La Roche Inc. Combination therapy of anti-HER3 antibodies
AU2014274660B2 (en) 2013-06-06 2019-05-16 Pierre Fabre Médicament Anti-C10orf54 antibodies and uses thereof
WO2015053871A2 (en) 2013-08-26 2015-04-16 MabVax Therapeutics, Inc. NUCLEIC ACIDS ENCODING HUMAN ANTIBODIES TO SIALYL-LEWISa
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
HUE055189T2 (hu) 2014-06-04 2021-11-29 Biontech Res And Development Inc Humán monoklonális antitestek a GD2 ganglioziddal ellen
DK3229838T3 (da) 2014-12-11 2020-10-19 Pf Medicament Anti-C10orf54-antistoffer og anvendelser deraf
EP3233829B1 (en) 2014-12-18 2019-08-14 Pfizer Inc Pyrimidine and triazine derivatives and their use as axl inhibitors
CN114504652A (zh) 2015-03-03 2022-05-17 科马布有限公司 抗体、用途和方法
CN109415437B (zh) 2015-12-02 2022-02-01 斯特库伯株式会社 与btn1a1免疫特异性结合的抗体和分子及其治疗用途
CN108925136B (zh) 2015-12-02 2022-02-01 斯特赛恩斯公司 特异于糖基化的btla（b和t淋巴细胞衰减因子）的抗体
US20180371551A1 (en) 2015-12-03 2018-12-27 Agios Pharmaceuticals, Inc. Mat2a inhibitors for treating mtap null cancer
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
US20200148768A1 (en) 2017-05-31 2020-05-14 Stcube & Co., Inc. Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
WO2018222685A1 (en) 2017-05-31 2018-12-06 Stcube & Co., Inc. Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1
CN110997724A (zh) 2017-06-06 2020-04-10 斯特库伯株式会社 使用结合btn1a1或btn1a1-配体的抗体和分子治疗癌症的方法
EP3694889A1 (en) 2017-10-13 2020-08-19 Boehringer Ingelheim International GmbH Human antibodies to thomsen-nouvelle (tn) antigen
CN112740043A (zh) 2018-07-20 2021-04-30 皮埃尔法布雷医药公司 Vista受体
WO2021155006A1 (en) 2020-01-31 2021-08-05 Les Laboratoires Servier Sas Inhibitors of cyclin-dependent kinases and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1884595A (en) * 1994-04-29 1995-11-29 Pfizer Inc. Novel acyclic and cyclic amides as neurotransmitter release enhancers
EP0760239A3 (en) * 1995-09-01 1999-04-14 Pfizer Inc. Therapeutic agents for use in cancer therapy

Also Published As

Publication number Publication date
CA2259222A1 (en) 1997-12-31
WO1997049700A1 (en) 1997-12-31
AU2710597A (en) 1998-01-14
US6071935A (en) 2000-06-06
EP0907649A1 (en) 1999-04-14
ID17053A (id) 1997-12-04
JPH11512750A (ja) 1999-11-02
MA26432A1 (fr) 2004-12-20
AP9701039A0 (en) 1997-07-31
TNSN97110A1 (fr) 2005-03-15
ZA975675B (en) 1998-01-28
BR9709974A (pt) 1999-08-10

Similar Documents

Publication Publication Date Title
GT199700074A (es) Derivados de 2-(2-oxo-etiliden)-imidazolidin-4-ona
AR023130A1 (es) Composiciones para promover el crecimiento
ID29393A (id) Komposisi pengobatan kanker dan metoda penggunaan minyak-minyak esensil tanaman alamiah
UY24805A1 (es) Peptidos y compuestos que se enlazan al receptor de la trombopoyetina
BR0116452A (pt) Composto, composição farmacêutica, uso de um composto
ES2157994T3 (es) Inhibidores tetra y pentapeptidos sustituidos de la proteina farnesiltransferasa.
TR199903331T2 (xx) Farnesil protein transferas engelleyicileri.
ECSP045520A (es) Metodos de tratamiento con inhibidores de la ptec y agentes antihipertensivos
BG104247A (en) Resorcinol derivatives
ES2191152T3 (es) Terapia combinada para el tratamiento de psicosis.
BRPI0207961A8 (pt) Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
HRP950337A2 (en) Histidine and homohistidine derivatives as inhibitors of protein farnesyltransferase
BR0208142A (pt) Combinações compreendendo um agente antidiarréico e epotilona ou derivado de epotilona
ID29552A (id) Senyawa-senyawa triazola dan penggunaannya
ES2177112T3 (es) Agentes angiostaticos y composiciones para tratar el glaucoma glc1a.
HUP0300917A2 (hu) Bradikardiakumok alkalmazása hipertrófiával társult miokardiális betegségek kezelésére és ezeket tartalmazó gyógyszerkészítmények
AR020563A1 (es) Compuestos (poli)tia-alquinoicos y sus derivados, composiciones que los incluyen y su utilizacion
BR9809848A (pt) Composição
AR000357A1 (es) Utilización de un antagonista de sustancia p para la preparación de una composición farmacéutica de aplicación topica para tratar las manchas rojas cutaneas de origen neurogeno y especialmente la rosacea y el eritema pudico
ES2175356T3 (es) Uso de (+)-alfa-(2,3-dimetoxifenil)-1-[2-(4 fluorofenil)et il[-4- piperidinmetanol en el tratamiento de trastornos depresivos y trastornos bipolares.
UY26648A1 (es) Inhibidores de vasopeptidasa para tratar hipertensión sistólica aislada
BR0009194A (pt) Composição do resorcinol
TR200002847T2 (tr) Biçim VI 5, 6-dikloro-2-(izopropilamino) -1-(beta-L-ribofüranosil) -1H-benzimidazol.
ID23184A (id) Garam-garam peptida bpc dengan aktivitas organoprotektif proses pembuatan dan penggunaannya dalam terapi
NO20005548L (no) Mykobakterieinhibitorer